Vensana Capital
VC Fund
Minneapolis, United States
Vensana Capital is a venture capital investment firm that focuses on healthcare with breakthrough innovations in medical technology.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 59%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Vensana Capital invests in
Stages Vensana Capital invests in
Countries Vensana Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Smith
|
|||
Cynthia Yee
|
|||
Greg Banker
|
|||
Justin Klein
|
|||
Kirk Nielsen
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 19 (49%)
- Medical Device 17 (44%)
- Medical 13 (33%)
- Biotechnology 6 (15%)
- Wellness 5 (13%)
Stage
- Series A 7 (18%)
- Series B 7 (18%)
- Series C 4 (10%)
- Venture - Series Unknown 3 (8%)
- Series D 2 (5%)
Country
- United States 20 (51%)
- France 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aaron Smith
Advisor
|
Advisor | Total investments: 0 | Find email | |
|
Cynthia Yee
Partner
|
Partner | Total investments: 4 | Find email | |
|
Greg Banker
Vice President
|
Vice President | Total investments: 3 | Find email | |
|
Justin Klein
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 26 | Find email | |
|
Kirk Nielsen
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 3 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TYBR Health
|
TYBR is a medical device company developing a sprayable hydrogel to keep internal organs scar-free after surgery. Internal scarring is the #1 complication of surgery, and TYBR's naturally derived solution reduces scarring by 75% preclinically. It was founded by Tim Keane and Alex Smith in Houston, Texas in 2020, | $30M / Series A / Jul 21, 2026 | |
Ventaris Surgical
|
Ventaris Surgical is a medical equipment company that provides surgical instruments to specialists. | $30.7M / Series A / Jan 09, 2026 | |
Apella Technology
|
Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $80M / Series B / Jan 07, 2026 | |
Okami Medical
|
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M / Series F / Nov 19, 2025 | |
|
Okami Medical
|
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M / Series F / Nov 19, 2025 | |
Luna Diabetes
|
Luna Diabetes is a manufacturer of medical equipment. | $23.6M / Series A / Aug 18, 2025 | |
Spyglass Pharma
|
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications. | $75M / Series D / Jun 02, 2025 | |
Evident Vascular
|
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. | Series B / Mar 25, 2025 | |
|
Evident Vascular
|
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. | Series B / Mar 25, 2025 | |
Alleviant Medical
|
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americanscurrently suffering from this disease. | $90M / Venture - Series Unknown / Jan 14, 2025 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Vensana Capital invest in?
Vensana Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 39 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vensana Capital?
Public channels for Vensana Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vensana Capital?
The team at Vensana Capital includes Aaron Smith (Advisor), Cynthia Yee (Partner) and Greg Banker (Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
